• Realbotix entered an unsecured bridge loan facility with Onconetix tied to the proposed merger announced Feb. 12, 2026.
• Facility uses an unsecured promissory note with an initial draw of USD 2.5 million, expandable to USD 5 million.
• Note is non-interest bearing, with automatic cancellation at merger closing without repayment by the borrower or guarantor.
• Termination of the merger triggers 12% annual interest on outstanding principal from the termination date.
• Realbotix guarantees payment under the note, with a covenant limiting additional indebtedness without Onconetix consent.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Realbotix Corp. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260914451410) on September 14, 2026, and is solely responsible for the information contained therein.